Two doses of sintilimab (intravenously, 200 mg) were used for patients with stages IA to IIIB NSCLC....In patients with positive PD-L1 expression, 3-year OS and DFS rates were 95.5% and 81.8%, respectively….According to the analysis based on DFS and EFS, our results indicated that patients with higher TMB could have more favorable clinical outcomes than patients with lower TMB (DFS, HR = 0.164 [95% CI: 0.019–1.414]...based on the 3-year follow-up, we are the first to present the long-term and comprehensive survival data for patients with NSCLC receiving PD-1 inhibitors as the neoadjuvant therapy, indicating the efficacy and feasibility of neoadjuvant sintilimab, especially for patients with high TMB and positive PD-L1 expression.